Medindia

X

GSK Encounters Initial Resistance Following Directional Shift, Says GlobalData Analyst

by Dr. Trupti Shirole on  February 12, 2015 at 8:22 AM Press Release   - G J E 4
GlaxoSmithKline plc (GSK) is realigning its operating structure with its corporate objectives and cashing in on its assets. Following a less than flattering financial performance in 2014, the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, informed an analyst with research and consulting firm GlobalData.
 GSK Encounters Initial Resistance Following Directional Shift, Says GlobalData Analyst
GSK Encounters Initial Resistance Following Directional Shift, Says GlobalData Analyst
Advertisement

In 2014, excluding divestments, GSK's total revenue fell by 10% year-on-year while operating profits were down by 15% on a pro forma basis. The growing strength of the pound sterling was largely to blame for lower revenues through the first three quarters of the year. Also, a large proportion of the company's decline was inorganic.

Advertisement
Chloe Thornton, MSc, GlobalData's Company Analyst, said, "Within its central pharmaceuticals business, GSK's greatest growth resistor was by far its flagship respiratory franchise, which fell by 10% year-on-year to just over £6 billion ($9.8 billion), excluding currency impact. GSK invested heavily in developing its respiratory pipeline, but the expectation that it could compensate for the imminent patent cliff facing Seretide/Advair appears optimistic. Sales of Breo Ellipta came to £67 million ($106 million), while Anoro earned just £17 million ($27 million) in 2014, well short of GSK's estimates. In addition, a further 26 pharmaceutical products witnessed year-on-year declines through 2014, at a total loss of £1.2 billion ($1.9 billion). Despite the strong performance of GSK's cancer therapeutics business, the company has agreed to divest its oncology assets to Novartis, while GSK is also considering divesting a share of its stake in its other best performing business, the ViiV Healthcare joint venture. The strength of GSK's oncology portfolio against a backdrop of decline elsewhere across its pharma business somewhat calls into question the decision to trade these assets to Novartis. However, the $16 billion capital boost GSK will derive from the deal when it is completed over the next few months should help to dispel those concerns, provided the company can proactively invest this capital in areas of high growth potential."

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All